JP2014534215A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534215A5
JP2014534215A5 JP2014538834A JP2014538834A JP2014534215A5 JP 2014534215 A5 JP2014534215 A5 JP 2014534215A5 JP 2014538834 A JP2014538834 A JP 2014538834A JP 2014538834 A JP2014538834 A JP 2014538834A JP 2014534215 A5 JP2014534215 A5 JP 2014534215A5
Authority
JP
Japan
Prior art keywords
indazol
composition
pyrimidinyl
methylamino
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014538834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534215A (ja
JP6200893B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/060361 external-priority patent/WO2013066616A1/en
Publication of JP2014534215A publication Critical patent/JP2014534215A/ja
Publication of JP2014534215A5 publication Critical patent/JP2014534215A5/ja
Application granted granted Critical
Publication of JP6200893B2 publication Critical patent/JP6200893B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014538834A 2011-10-31 2012-10-16 パゾパニブ製剤 Expired - Fee Related JP6200893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
US61/553,454 2011-10-31
PCT/US2012/060361 WO2013066616A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017093456A Division JP6423484B2 (ja) 2011-10-31 2017-05-10 パゾパニブ製剤

Publications (3)

Publication Number Publication Date
JP2014534215A JP2014534215A (ja) 2014-12-18
JP2014534215A5 true JP2014534215A5 (enExample) 2015-11-12
JP6200893B2 JP6200893B2 (ja) 2017-09-20

Family

ID=48192602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014538834A Expired - Fee Related JP6200893B2 (ja) 2011-10-31 2012-10-16 パゾパニブ製剤
JP2017093456A Expired - Fee Related JP6423484B2 (ja) 2011-10-31 2017-05-10 パゾパニブ製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017093456A Expired - Fee Related JP6423484B2 (ja) 2011-10-31 2017-05-10 パゾパニブ製剤

Country Status (12)

Country Link
US (3) US9278099B2 (enExample)
EP (1) EP2773204A4 (enExample)
JP (2) JP6200893B2 (enExample)
KR (1) KR101993436B1 (enExample)
CN (1) CN104254249B (enExample)
AU (1) AU2012332952B2 (enExample)
BR (1) BR112014010551A2 (enExample)
CA (1) CA2852912A1 (enExample)
HK (1) HK1201685A1 (enExample)
IN (1) IN2014CN02850A (enExample)
RU (1) RU2616500C2 (enExample)
WO (1) WO2013066616A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201502073B (en) * 2014-03-28 2016-03-30 Cipla Ltd Pharmaceutical composition
CN110753546B (zh) * 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
IL278161B2 (en) 2018-04-24 2024-12-01 Shionogi & Co Solid dosage form with excellent stability
AU2019259686B2 (en) 2018-04-24 2023-05-25 Shionogi & Co., Ltd. Solid formulation having excellent stability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (enExample) 1988-03-25 1990-10-15 Ciba Geigy Ag
DE58903964D1 (de) * 1988-11-10 1993-05-06 Ciba Geigy Ag Fluessige orale formulierung.
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
ATE500831T1 (de) * 2005-11-29 2011-03-15 Glaxosmithkline Llc Krebsbehandlungsverfahren
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
US20100291025A1 (en) 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Similar Documents

Publication Publication Date Title
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2014534215A5 (enExample)
WO2015120110A3 (en) Novel pharmaceutical formulations
MX2009000035A (es) Formulaciones de agente activo, procedimientos de preparacion y procedimientos de uso.
SG170047A1 (en) Nanoparticulate posaconazole formulations
JP2016516765A5 (enExample)
JP2013525493A5 (enExample)
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
JP2018021007A5 (enExample)
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
JP2012505172A5 (enExample)
JP2013535472A5 (enExample)
FI3943070T3 (fi) Pitkävaikutteisia bedakiliiniformulaatioita
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
JP2017528497A (ja) 長時間作用型医薬組成物
RU2014115289A (ru) Композиция пазопаниба
JP2016188259A (ja) 水性眼科組成物
MX2014001065A (es) Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.
JP2008538751A5 (enExample)
RU2007137846A (ru) Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
TW200640459A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconazole
JP2010265261A (ja) レボカバスチン懸濁型点眼剤
MA32722B1 (fr) Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion